15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Denali Therapeutics Inc, 12 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $23.00 to $42.00, a moderate spread. The average target of $35.25 sits 60% above the current $22.08. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 11 to 12 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.62 next quarter toward $-2.43 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Strong Buy
Strong Buy00%
Buy1292%
Hold18%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Denali Therapeutics Inc.
As of Sep, 12 of 13 firms rate DNLI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DNLI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.62
Range $-0.78 – $-0.46 · 17 analysts · -15% YoY
Next period, 17 analysts expect Denali Therapeutics Inc to earn $-0.62 a share (range $-0.78 – $-0.46), versus $-0.73 a year earlier. Full-year consensus is $-2.35, growing to $-2.43 the year after.
REVENUE · NEXT QUARTER
$24.2M
Range $10.8M – $75.4M · 17 analysts
Revenue is expected to reach $24.2M (range $10.8M – $75.4M). Full-year consensus is $50.3M, rising to $126.9M next year.
Top analysts covering Denali Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DNLI.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$35.00+58.5% to target
Overall win rate
50%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$42.00+90.2% to target
Overall win rate
46%
+ Follow
#3
Jessica Fye
JP Morgan · Rank #71
Buy
$29.00+31.3% to target
Overall win rate
53%
+ Follow
#4
Laura Chico
Wedbush · Rank #74
Buy
$26.00+17.8% to target
Overall win rate
44%
+ Follow
#5
Joel Beatty
Baird · Rank #80
Buy
$34.00+54.0% to target
Overall win rate
48%
+ Follow
DNLI stock forecast FAQ
What is DNLI's average 12-month price target?+
The 12 analysts with a live target average $35.25 for Denali Therapeutics Inc over the next 12 months, ranging from a $42.00 high to a $23.00 low.
Is DNLI stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 13 analyst ratings, 12 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DNLI?+
The Street-high target is $42.00 (HC Wainwright & Co.), and the Street-low is $23.00 (Wedbush). The average of all 12 active targets is $35.25.
How many Wall Street analysts cover DNLI?+
13 analysts have an active rating on Denali Therapeutics Inc, and 12 firms carry a live 12-month price target.
Who is the most accurate analyst covering DNLI?+
Among analysts who currently cover DNLI, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $35.00 target.
What is Denali Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.62 per share (range $-0.78 – $-0.46) across 17 analysts. Full-year EPS is projected at $-2.35, rising to $-2.43 the following year.
How much revenue is Denali Therapeutics Inc expected to report next quarter?+
Consensus revenue is $24.2M (range $10.8M – $75.4M). Full-year revenue is projected at $50.3M, growing to $126.9M next year.
Have analysts been upgrading or downgrading DNLI lately?+
As of Sep, 12 of 13 firms rate DNLI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DNLI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
